Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer
Background Programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) blockade therapy fails in the majority of patients with cancer. Oncolytic viruses represent a new class of therapeutic agents, yet the therapeutic efficacy is still disappointing. Moreover, intratumoral injection of viruses...
| Egile Nagusiak: | , , , , , |
|---|---|
| Formatua: | Artikulua |
| Hizkuntza: | English |
| Argitaratua: |
BMJ Publishing Group
2020-05-01
|
| Saila: | Journal for ImmunoTherapy of Cancer |
| Sarrera elektronikoa: | https://jitc.bmj.com/content/8/1/e000294.full |